Ep 38. Is risankizumab safe and effective for active psoriatic arthritis? Results from the KEEPsAKE 2 study

Talking Rheumatology Research

Content provided by British Society for Rheumatology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by British Society for Rheumatology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

1+ y ago 7:19

MP3•Episode home

Dr Andrew Östör joins Dr Marwan Bukhari to discuss their article, chosen as the June Editor's Choice article, which evaluates the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one or more conventional synthetic DMARDs (csDMARD-IR).

Listen now to hear the findings and what this means for future clinical practice!

You can read this article [https://doi.org/10.1093/rheumatology/keac605] in Rheumatology.

Thanks for listening to Talking Rheumatology Research! Join the conversation on X using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram and LinkedIn.
Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

50 episodes

#Fitness #Medicine #British Society For Rheumatology #Rheumatology #Research #Arthritis #Lupus #Journalism #Disease #Science #Myositis #Vasculitis #Bsr